# Top Harvest Capital

> Top Harvest Capital is a VC fund in Menlo Park backing Artificial Intelligence and Biotechnology. See 22 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Menlo Park, United States
- Total investments: 22
- Last investment: Feb 2026
- Lead investor: 18%
- Last updated: Aug 2026
- Website: https://www.topharvestcap.com/

Top Harvest Capital is a VC fund in Menlo Park focused on Artificial Intelligence and Biotechnology. Top Harvest Capital invests worldwide in early-stage startups leveraging machine learning / AI.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $4.3M–$29M |
| Series A | $13M–$20M |
| Series B | $30M–$60M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 10 | 45% |
| Biotechnology | 6 | 27% |
| Health Care | 5 | 23% |
| Machine Learning | 5 | 23% |
| Software | 4 | 18% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 14 | 64% |
| Series A | 3 | 14% |
| Series B | 2 | 9% |
| Funding Round | 1 | 5% |
| Venture - Series Unknown | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 59% |
| France | 3 | 14% |
| Indonesia | 1 | 5% |
| Switzerland | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BreezeBio | GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $60M | Series B | Feb 25, 2026 |  |
| Syntracts | Syntracts is doing what legal AI has promised — but not delivered. We cut through the noise with a proprietary platform that doesn’t rely on prompts or third-party APIs. We turn contracts — some of the most valuable but inaccessible assets for any enterprise — into structured data with over 95% accuracy, enabling downstream workflows likenegotiation, compliance, risk, and analytics from a single source of truth. Our system adapts to each customer’s specific contracts by delivering hundreds of custom AI agents fine-tuned with synthetic legal data, ensuring unmatched security, precision, and scalability. | $6.7M | Seed | Oct 21, 2025 |  |
| Syntracts Inc. | Syntracts is doing what legal AI has promised — but not delivered. We cut through the noise with a proprietary platform that doesn’t rely on prompts or third-party APIs. We turn contracts — some of the most valuable but inaccessible assets for any enterprise — into structured data with over 95% accuracy, enabling downstream workflowslikenegotiation, compliance, risk, and analytics from a single source of truth. Our system adapts to each customer’s specific contracts by delivering hundreds of custom AI agents fine-tuned with synthetic legal data, ensuring unmatched security, precision, and scalability. | $5.3M | Seed | Oct 21, 2025 |  |
| Ryght AI | Synthetica Bio develops an enterprise-scale generative AI for biopharma. It empowers discovery, clinical, and commercial teams with actionable knowledge in real-time. Its platform fine-tunes LLMs for real-time data with the verified and secure customer data store. | $3M | Seed | Jun 12, 2025 |  |
| Hedera Dx | With the use of Hedera Dx's liquid biopsy solution, hospital labs will be able to conduct clinically useful liquid biopsies on their own. This will greatly simplify tumor profiling. It is difficult to accomplish IVD compliance, privacy infrastructure, and validation, and even if these challenges are overcome, the current software workflows areinefficient to use and lack key capabilities.Hedera Dx was established on July 1, 2021 in Epalinges, Vaud. | $17M | Series A | May 27, 2025 |  |
| Youlify | Youlify offers AI solutions for medical billing, denied claims investigation, and real-time financial insights. | $4.3M | Seed | Apr 16, 2025 |  |
| Voxel51 | Voxel51 is the leading data platform for physical AI. The company's flagship product, FiftyOne, combines open-source flexibility with enterprise-grade capabilities to help teams understand and analyze their multimodal data, annotate the right samples, close quality and coverage gaps, and build models that perform reliably in the real world.Trusted by millions of developers and thousands of enterprises—including Porsche, Vivint, Berkshire Grey, and Microsoft—FiftyOne is how the world's leading AI teams build the data foundation physical AI demands. Learn more at voxel51.com. | $30M | Series B | May 16, 2024 |  |
| Leash Biosciences | Leash Biosciences engages in machine learning to solve medicinal chemistry. | $9.3M | Seed | Apr 05, 2024 |  |
| Leash Bio | Leash Biosciences engages in machine learning to solve medicinal chemistry. | $9.3M | Seed | Apr 05, 2024 |  |
| Bioptimus | Bioptimus is a developer of a universal AI foundation model that connects biology at all sizes, from molecules to cells, tissues, and entire organisms. The company's technology turns multiscale data into actionable representations, allowing clients to spark breakthrough discoveries and expedite biomedical innovation. | $35M | Seed | Feb 20, 2024 |  |

10 of 22 investments shown.

## Co-investors
- [Cathay Innovation](https://shizune.co/investors/profile/cathay-innovation-fund) — VC Fund, 3 deals together
- [Drive Capital](https://shizune.co/investors/profile/drive-capital) — VC Fund, 3 deals together
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund, 3 deals together
- [Page One Ventures](https://shizune.co/investors/profile/page-one-ventures) — VC Fund, 3 deals together
- [Air Street Capital](https://shizune.co/investors/profile/air-street-capital) — VC Fund, 2 deals together
- [AIX Ventures](https://shizune.co/investors/profile/aix-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [East Ventures](https://shizune.co/investors/profile/east-ventures) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [AC Ventures](https://shizune.co/investors/profile/acventures) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Indonesia](https://shizune.co/investors/biotechnology-investors-indonesia)
- [Biotechnology VC Funds in Indonesia](https://shizune.co/investors/biotechnology-vc-funds-indonesia)
- [Biotech Investors in Indonesia](https://shizune.co/investors/biotech-investors-indonesia)
- [Biotech VC Funds in Indonesia](https://shizune.co/investors/biotech-vc-funds-indonesia)

## FAQ

### What does Top Harvest Capital invest in?

Top Harvest Capital invests primarily in Artificial Intelligence, Biotechnology and Health Care startups, most often at Seed and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Top Harvest Capital's check size?

Top Harvest Capital typically joins rounds of $4.3M–$29M at Seed, $13M–$20M at Series A and $30M–$60M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Top Harvest Capital participates in.

### When did Top Harvest Capital last invest?

The most recent investment recorded for Top Harvest Capital closed in Feb 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co